CARA - DD - August 2021
OS: 50M
Float: 49M
Cash OK at around $130M (offering not likely right now)
Upcoming catalysts:
ER (and corporate update) on August 9, 2021
PDUFA on August 23, 2021 - met primary endpoints for Phase 3
" we were very pleased with the FDA acceptance, with Priority Review, of our first NDA filing for our lead product candidate, KORSUVA™ Injection, for the treatment of moderate-to-severe pruritus in hemodialysis patients. With an expected Prescription Drug User Fee Act (PDUFA) target action date of August 23, 2021, we remain focused, along with our commercial partner, Vifor Pharma, on preparation for the U.S. launch of KORSUVA Injection in the second half of 2021, if approved"
Cash OK at around $130M (offering not likely right now)
Upcoming catalysts:
ER (and corporate update) on August 9, 2021
PDUFA on August 23, 2021 - met primary endpoints for Phase 3
" we were very pleased with the FDA acceptance, with Priority Review, of our first NDA filing for our lead product candidate, KORSUVA™ Injection, for the treatment of moderate-to-severe pruritus in hemodialysis patients. With an expected Prescription Drug User Fee Act (PDUFA) target action date of August 23, 2021, we remain focused, along with our commercial partner, Vifor Pharma, on preparation for the U.S. launch of KORSUVA Injection in the second half of 2021, if approved"
Cara Therapeutics - CARA
| Total Followers: | 0 |
|
|
|
| Follow | |